Korrektur
Correction to: Impact of KRAS codon-specific mutations on survival in metastatic CRC on trifluridine-tipiracil with/without bevacizumab
JNCI: Journal of the National Cancer Institute · 12.11.2026
DOI: 10.1093/jnci/djag367 ↗Kurz gefasst
Korrektur in der Zeitschrift JNCI: Journal of the National Cancer Institute, online erschienen am 12.11.2026. Die Arbeit nennt 3 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Zitieren
APA
(2026). Correction to: Impact of KRAS codon-specific mutations on survival in metastatic CRC on trifluridine-tipiracil with/without bevacizumab. JNCI: Journal of the National Cancer Institute. https://doi.org/10.1093/jnci/djag367
Vancouver
Correction to: Impact of KRAS codon-specific mutations on survival in metastatic CRC on trifluridine-tipiracil with/without bevacizumab. JNCI: Journal of the National Cancer Institute. 2026. doi:10.1093/jnci/djag367
BibTeX
@article{euvimed2026,
title = {Correction to: Impact of KRAS codon-specific mutations on survival in metastatic CRC on trifluridine-tipiracil with/without bevacizumab},
journal = {JNCI: Journal of the National Cancer Institute},
year = {2026},
doi = {10.1093/jnci/djag367}
}
EUVIMED